BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16182328)

  • 1. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells.
    Wolfesberger B; Walter I; Hoelzl C; Thalhammer JG; Egerbacher M
    Res Vet Sci; 2006 Jun; 80(3):308-16. PubMed ID: 16182328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
    Naruse T; Nishida Y; Hosono K; Ishiguro N
    Carcinogenesis; 2006 Mar; 27(3):584-92. PubMed ID: 16219634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro effects of piroxicam and meloxicam on canine cell lines.
    Knottenbelt C; Chambers G; Gault E; Argyle DJ
    J Small Anim Pract; 2006 Jan; 47(1):14-20. PubMed ID: 16417605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
    Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells.
    Naruse T; Nishida Y; Ishiguro N
    Biomed Pharmacother; 2007 Jul; 61(6):338-46. PubMed ID: 17395421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells.
    Wolfesberger B; Hoelzl C; Walter I; Reider GA; Fertl G; Thalhammer JG; Skalicky M; Egerbacher M
    J Vet Pharmacol Ther; 2006 Feb; 29(1):15-23. PubMed ID: 16420297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
    Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
    Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
    Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
    Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines.
    Massimini M; Palmieri C; De Maria R; Romanucci M; Malatesta D; De Martinis M; Maniscalco L; Ciccarelli A; Ginaldi L; Buracco P; Bongiovanni L; Della Salda L
    Vet Pathol; 2017 May; 54(3):405-412. PubMed ID: 28438108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.
    Hosoya K; Murahari S; Laio A; London CA; Couto CG; Kisseberth WC
    Am J Vet Res; 2008 Apr; 69(4):519-26. PubMed ID: 18380584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lycopene on proliferation and death of canine osteosarcoma cells.
    Wakshlag JJ; Balkman CE
    Am J Vet Res; 2010 Nov; 71(11):1362-70. PubMed ID: 21034328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
    Wolfesberger B; Tonar Z; Gerner W; Skalicky M; Heiduschka G; Egerbacher M; Thalhammer JG; Walter I
    Res Vet Sci; 2010 Feb; 88(1):94-100. PubMed ID: 19665156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
    Saito T; Tamura D; Asano R
    Oncol Rep; 2014 Apr; 31(4):1637-44. PubMed ID: 24503782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.
    Liu JF; Zhang SW; Jamieson GG; Zhu GJ; Wu TC; Zhu TN; Shan BE; Drew PA
    Int J Cancer; 2008 Apr; 122(7):1639-44. PubMed ID: 18058818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation.
    Pang LY; Gatenby EL; Kamida A; Whitelaw BA; Hupp TR; Argyle DJ
    PLoS One; 2014; 9(1):e83144. PubMed ID: 24416158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of meloxicam on aluminum overload-induced cerebral damage in mice.
    Jun-Qing Y; Bei-Zhong L; Bai-Cheng H; Qi-Qin Z
    Eur J Pharmacol; 2006 Oct; 547(1-3):52-8. PubMed ID: 16928369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells.
    Kobayashi M; Nakamura S; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Ohnishi K
    Eur J Haematol; 2005 Sep; 75(3):212-20. PubMed ID: 16104877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited inhibitory effects of non-steroidal antiinflammatory drugs on in vitro osteogenic differentiation in canine cells.
    Oh N; Sunaga T; Yamazaki H; Hosoya K; Takagi S; Okumura M
    Jpn J Vet Res; 2013 Aug; 61(3):97-107. PubMed ID: 24059095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meloxicam inhibits the growth of non-small cell lung cancer.
    Tsubouchi Y; Mukai S; Kawahito Y; Yamada R; Kohno M; Inoue K; Sano H
    Anticancer Res; 2000; 20(5A):2867-72. PubMed ID: 11062695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melarsomine suppresses canine osteosarcoma cell survival via inhibition of Hedgehog-GLI signaling.
    Nam A; Kim T; Li Q; Rebhun RB; Youn HY; Seo KW
    J Vet Med Sci; 2019 Dec; 81(12):1722-1729. PubMed ID: 31645504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.